Company Overview
Unlearn is an AI company that develops machine learning-generated digital twins of clinical trial participants, enabling pharmaceutical companies to run smaller, faster, and more statistically powerful trials. Its TwinRCT solution uses PROCOVA — a covariate adjustment methodology now officially qualified by the European Medicines Agency for use in Phase 2 and 3 trials with continuous outcomes — to augment or replace traditional placebo control arms with AI-generated synthetic patient profiles. The FDA has provided positive feedback supporting PROCOVA''s use in covariate-adjusted analyses across clinical development. Unlearn has built its strongest traction in neuroscience — Alzheimer''s disease and ALS — where small patient populations and high mortality rates make trial efficiency critical. The company has raised approximately $100M across two $50M funding rounds, with the most recent round in 2024.
Key Differentiators
Strong Challenger
Unlearn is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Unlearn with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Unlearn? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Unlearn Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Unlearn vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →